Amgen Inc. $AMGN Shares Sold by Access Financial Services Inc.

Access Financial Services Inc. reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 46.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,066 shares of the medical research company’s stock after selling 1,820 shares during the quarter. Access Financial Services Inc.’s holdings in Amgen were worth $676,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Capital World Investors boosted its stake in Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares during the period. National Bank of Canada FI grew its stake in Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after buying an additional 863,216 shares during the last quarter. Van ECK Associates Corp increased its position in Amgen by 71.8% in the third quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after buying an additional 567,400 shares during the period. Fisher Asset Management LLC increased its position in Amgen by 91.6% in the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock worth $221,607,000 after buying an additional 375,463 shares during the period. Finally, Danske Bank A S bought a new stake in Amgen in the third quarter valued at $101,076,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

AMGN stock opened at $347.94 on Monday. The company has a 50-day simple moving average of $363.65 and a 200 day simple moving average of $333.18. The company has a market capitalization of $187.56 billion, a P/E ratio of 24.45, a PEG ratio of 3.45 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on AMGN shares. Guggenheim boosted their price target on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Daiwa Securities Group increased their price objective on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Barclays started coverage on shares of Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective on the stock. HSBC restated a “buy” rating and issued a $425.00 target price on shares of Amgen in a research report on Wednesday, December 10th. Finally, UBS Group raised their price target on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.